LPA disruption with AAV-CRISPR potently lowers plasma apo(a) in transgenic mouse model: A proof-of-concept study

LPA disruption with AAV-CRISPR potently lowers plasma apo(a) in transgenic mouse model: A proof-of-concept study

Lipoprotein(a) (Lp(a)) represents a unique subclass of circulating lipoprotein particles and consists of an apolipoprotein(a) (apo(a)) molecule covalently bound to apolipoprotein B-100. The metabolism of Lp(a) particles is distinct from that of low-density lipoprotein (LDL) cholesterol, and currentl...

Full description

Bibliographic Details
Main Authors: Alexandria M. Doerfler, So Hyun Park, Julia M. Assini, Amer Youssef, Lavanya Saxena, Adam B. Yaseen, Marco De Giorgi, Marcel Chuecos, Ayrea E. Hurley, Ang Li, Santica M. Marcovina, Gang Bao, Michael B. Boffa, Marlys L. Koschinsky, William R. Lagor
Format: Article
Language:English
Published: Elsevier 2022-12-01
Series:Molecular Therapy: Methods & Clinical Development
Subjects:
lipoprotein(a)
LPA
apolipoprotein(a)
liver
gene therapy
adeno-associated virus
Online Access:http://www.sciencedirect.com/science/article/pii/S2329050122001516

Internet

http://www.sciencedirect.com/science/article/pii/S2329050122001516

Similar Items